Massachusetts And Paris


NATICK, Massachusetts and PARIS, May 23, 2011 - - 12-Month Clinical Data Demonstrate Low Adverse Event Rates for Boston Scientific's 2.25 mm PROMUS Element Platinum Chromium Stent Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from its PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element(TM) Everolimus-Eluting Platinum Chromium Stent System in treating small vessel coronary disease.
Older News
S M T W T F S
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
Copyright© 2011 The Gaea Times